Lion Biotechnologies Inc., of New York, presented data from a phase II study at the Inaugural International Cancer Immunotherapy Conference in New York showing that its tumor-infiltrating lymphocyte (TIL) therapy in heavily pre-treated patients with metastatic melanoma was associated with high, durable objective response rates (ORRs), including in patients who were refractory to checkpoint inhibitors.